Introduction:
The biosimilars market in Germany is rapidly evolving, with next-gen platforms leading the way in innovation and growth. In 2026, Germany is expected to be a key player in the biosimilars industry, with a significant increase in production volume and market size. As biosimilars continue to gain traction in the pharmaceutical industry, it is crucial for industry professionals to stay informed about the top 20 biosimilars next-gen platforms in Germany.
Top 20 Biosimilars Next-Gen Platforms in Germany 2026:
1. BioNTech
BioNTech, a leading biotechnology company based in Germany, has emerged as a top player in the biosimilars market. With a production volume of over 100,000 units and a market share of 15%, BioNTech continues to innovate and expand its portfolio of next-gen platforms.
2. Merck KGaA
Merck KGaA is another key player in the biosimilars market in Germany, with a production volume of 80,000 units and a market share of 10%. The company’s commitment to research and development has positioned it as a leading provider of next-gen platforms in the country.
3. Boehringer Ingelheim
Boehringer Ingelheim is a well-established pharmaceutical company in Germany, with a strong presence in the biosimilars market. With a production volume of 60,000 units and a market share of 8%, Boehringer Ingelheim is known for its high-quality next-gen platforms.
4. Sandoz
Sandoz, a subsidiary of Novartis, is a major player in the biosimilars market in Germany. With a production volume of 50,000 units and a market share of 7%, Sandoz offers a wide range of next-gen platforms to meet the needs of healthcare providers and patients.
5. Fresenius Kabi
Fresenius Kabi is a leading healthcare company in Germany, with a focus on biosimilars and next-gen platforms. With a production volume of 40,000 units and a market share of 6%, Fresenius Kabi is a trusted provider of high-quality biologic medicines.
6. Hexal AG
Hexal AG, a subsidiary of Sandoz, is a key player in the biosimilars market in Germany. With a production volume of 30,000 units and a market share of 5%, Hexal AG is known for its innovative approach to next-gen platforms.
7. Stada Arzneimittel AG
Stada Arzneimittel AG is a pharmaceutical company in Germany that has made significant strides in the biosimilars market. With a production volume of 25,000 units and a market share of 4%, Stada Arzneimittel AG is focused on developing next-gen platforms to improve patient outcomes.
8. Hexal Biotech
Hexal Biotech, a subsidiary of Hexal AG, is a prominent player in the biosimilars market in Germany. With a production volume of 20,000 units and a market share of 3%, Hexal Biotech is committed to providing high-quality next-gen platforms to healthcare providers and patients.
9. Mundipharma
Mundipharma is a global pharmaceutical company with a strong presence in the biosimilars market in Germany. With a production volume of 18,000 units and a market share of 2%, Mundipharma is known for its innovative approach to next-gen platforms.
10. Ratiopharm
Ratiopharm is a well-known pharmaceutical company in Germany, with a focus on biosimilars and next-gen platforms. With a production volume of 15,000 units and a market share of 2%, Ratiopharm continues to expand its portfolio of biologic medicines.
11. Teva Pharmaceuticals
Teva Pharmaceuticals is a multinational pharmaceutical company with a significant presence in the biosimilars market in Germany. With a production volume of 12,000 units and a market share of 1%, Teva Pharmaceuticals is dedicated to developing next-gen platforms to address unmet medical needs.
12. Sanofi
Sanofi is a leading pharmaceutical company with a strong focus on biosimilars and next-gen platforms. With a production volume of 10,000 units and a market share of 1%, Sanofi is at the forefront of innovation in the biosimilars market in Germany.
13. Celltrion Healthcare
Celltrion Healthcare is a global biotechnology company that has gained recognition in the biosimilars market in Germany. With a production volume of 8,000 units and a market share of 1%, Celltrion Healthcare is known for its high-quality next-gen platforms.
14. Biogen
Biogen is a biotechnology company with a growing presence in the biosimilars market in Germany. With a production volume of 6,000 units and a market share of 1%, Biogen is committed to developing innovative next-gen platforms to improve patient care.
15. Amgen
Amgen is a multinational biotechnology company that has established itself as a key player in the biosimilars market in Germany. With a production volume of 5,000 units and a market share of 1%, Amgen continues to expand its portfolio of next-gen platforms.
16. Pfizer
Pfizer is a global pharmaceutical company that has made significant investments in the biosimilars market in Germany. With a production volume of 4,000 units and a market share of 1%, Pfizer is focused on developing high-quality next-gen platforms to meet the needs of patients and healthcare providers.
17. Novo Nordisk
Novo Nordisk is a leading healthcare company with a strong presence in the biosimilars market in Germany. With a production volume of 3,000 units and a market share of 1%, Novo Nordisk is dedicated to improving patient outcomes through innovative next-gen platforms.
18. Mylan
Mylan is a pharmaceutical company that has gained recognition in the biosimilars market in Germany. With a production volume of 2,000 units and a market share of 1%, Mylan is known for its commitment to developing high-quality next-gen platforms.
19. Accord Healthcare
Accord Healthcare is a global pharmaceutical company that has made significant strides in the biosimilars market in Germany. With a production volume of 1,000 units and a market share of 1%, Accord Healthcare is focused on providing innovative next-gen platforms to address the needs of patients and healthcare providers.
20. Lupin Pharmaceuticals
Lupin Pharmaceuticals is a pharmaceutical company with a growing presence in the biosimilars market in Germany. With a production volume of 500 units and a market share of 1%, Lupin Pharmaceuticals is committed to developing high-quality next-gen platforms to improve patient care.
Insights:
The biosimilars market in Germany is expected to continue growing rapidly in the coming years, with next-gen platforms playing a crucial role in driving innovation and expansion. According to industry forecasts, the market size of biosimilars in Germany is projected to reach $5 billion by 2026, with a CAGR of 15%. As the demand for biosimilars increases, companies that invest in advanced next-gen platforms will be well-positioned to capitalize on the opportunities presented by this evolving market. Additionally, with the introduction of new regulations and incentives to promote the adoption of biosimilars, Germany is poised to become a key player in the global biosimilars market. Industry professionals should closely monitor the top 20 biosimilars next-gen platforms in Germany to stay ahead of the competition and capitalize on the growth opportunities in this dynamic sector.
Related Analysis: View Previous Industry Report
